DOP2011000229A - Composicion farmaceutica solida que comprende amlodipina y losartan - Google Patents

Composicion farmaceutica solida que comprende amlodipina y losartan

Info

Publication number
DOP2011000229A
DOP2011000229A DO2011000229A DO2011000229A DOP2011000229A DO P2011000229 A DOP2011000229 A DO P2011000229A DO 2011000229 A DO2011000229 A DO 2011000229A DO 2011000229 A DO2011000229 A DO 2011000229A DO P2011000229 A DOP2011000229 A DO P2011000229A
Authority
DO
Dominican Republic
Prior art keywords
losartan
pharmaceutical composition
solid pharmaceutical
amlodipina
composition including
Prior art date
Application number
DO2011000229A
Other languages
English (en)
Inventor
Jae Hyun Park
Kyeong Soo Kim
Ho Taek Yim
Ji Hyun Im
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42306870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2011000229(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of DOP2011000229A publication Critical patent/DOP2011000229A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invenciõn se relaciona con una composición farmacéutica sólida para la prevención y tratamiento de desórdenes cardiovasculares que comprenden formas granulares de amlodipina y losartan las cuales separadas la una de la otra, y un agente estabilizador, el cual ha mejorado la estabilidad de almacenamiento debido a ¡nteracción minimizada entre la amlodipina y el losartan.
DO2011000229A 2009-01-23 2011-07-18 Composicion farmaceutica solida que comprende amlodipina y losartan DOP2011000229A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090005840 2009-01-23
KR1020090036011A KR101232296B1 (ko) 2009-01-23 2009-04-24 안정성이 향상된 암로디핀 및 로자탄을 함유하는 고형 약제학적 조성물

Publications (1)

Publication Number Publication Date
DOP2011000229A true DOP2011000229A (es) 2011-10-15

Family

ID=42306870

Family Applications (3)

Application Number Title Priority Date Filing Date
DO2011000231A DOP2011000231A (es) 2009-01-23 2011-07-18 Composicion farmaceutica solida que comprende amlodipina y losartan con estabilidad mejorada
DO2011000230A DOP2011000230A (es) 2009-01-23 2011-07-18 Composicion farmaceutica solida que contiene amlodipina y losartan, asi como el proceso para producir la misma
DO2011000229A DOP2011000229A (es) 2009-01-23 2011-07-18 Composicion farmaceutica solida que comprende amlodipina y losartan

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DO2011000231A DOP2011000231A (es) 2009-01-23 2011-07-18 Composicion farmaceutica solida que comprende amlodipina y losartan con estabilidad mejorada
DO2011000230A DOP2011000230A (es) 2009-01-23 2011-07-18 Composicion farmaceutica solida que contiene amlodipina y losartan, asi como el proceso para producir la misma

Country Status (33)

Country Link
US (3) US9161933B2 (es)
EP (3) EP2413931B1 (es)
JP (3) JP5658172B2 (es)
KR (2) KR101232296B1 (es)
CN (4) CN102292085B (es)
AR (3) AR070897A1 (es)
AU (3) AU2009338267B2 (es)
BR (3) BRPI0924136B8 (es)
CA (3) CA2749903C (es)
CL (1) CL2011001781A1 (es)
CO (3) CO6361905A2 (es)
CR (3) CR20110450A (es)
DO (3) DOP2011000231A (es)
EA (3) EA020103B1 (es)
EC (1) ECSP11011253A (es)
ES (3) ES2580777T3 (es)
HK (1) HK1163539A1 (es)
HN (2) HN2011002022A (es)
IL (3) IL214146A0 (es)
JO (2) JO3328B1 (es)
MA (3) MA33056B1 (es)
MX (3) MX349221B (es)
MY (3) MY173823A (es)
NI (3) NI201100144A (es)
NZ (3) NZ594738A (es)
PE (4) PE20140978A1 (es)
SA (1) SA110310070B1 (es)
SG (3) SG173044A1 (es)
TW (3) TWI404534B (es)
UA (3) UA102721C2 (es)
UY (2) UY32388A (es)
WO (3) WO2010085014A1 (es)
ZA (3) ZA201106161B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2413931B1 (en) 2009-01-23 2016-06-01 Hanmi Science Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
JP6106359B2 (ja) * 2010-12-13 2017-03-29 第一三共ヘルスケア株式会社 ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
JP6041591B2 (ja) * 2011-09-13 2016-12-14 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
KR101907881B1 (ko) * 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
KR101392364B1 (ko) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물
JP6160263B2 (ja) * 2012-06-07 2017-07-12 大正製薬株式会社 ロキソプロフェン含有医薬組成物
KR101506148B1 (ko) * 2013-09-24 2015-03-26 대봉엘에스 주식회사 직접 타정할 수 있는 암로디핀 및 로사르탄을 포함하는 약제학적 조성물, 및 이에 의해 제조된 정제
WO2015072700A1 (en) * 2013-11-15 2015-05-21 Hanmi Pharm. Co., Ltd. Composite formulation comprising tadalafil and amlodipine
KR20150056443A (ko) * 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
KR102369607B1 (ko) * 2014-09-30 2022-03-03 한미약품 주식회사 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물
CN104610130A (zh) * 2015-01-22 2015-05-13 华东理工常熟研究院有限公司 氨氯地平-棕榈酸离子液体及其制备方法和用途
KR101914930B1 (ko) 2015-03-31 2018-11-05 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제
WO2017003186A1 (en) * 2015-06-30 2017-01-05 Hanmi Pharm. Co., Ltd. Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
KR101750689B1 (ko) * 2015-09-15 2017-06-26 주식회사 종근당 약제학적 복합제제
CN107260735A (zh) * 2017-07-25 2017-10-20 合肥华方医药科技有限公司 生物利用度提高的二氢吡啶类药物组合物
CN107308159A (zh) * 2017-07-28 2017-11-03 合肥华方医药科技有限公司 一种提高伊拉地平生物利用度药物组合物
CN107308158A (zh) * 2017-07-28 2017-11-03 合肥华方医药科技有限公司 一种提高非洛地平生物利用度的药物组合物
JP7166754B2 (ja) 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
CN108542891A (zh) * 2018-06-07 2018-09-18 董贵雨 一种含有替格瑞洛的固体药物组合物
JP2020090471A (ja) * 2018-12-07 2020-06-11 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법
KR20210074428A (ko) 2019-12-11 2021-06-22 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
KR20210152943A (ko) 2020-06-09 2021-12-16 한미약품 주식회사 암로디핀, 로사르탄 및 클로르탈리돈을 단층정에 포함하는 심혈관계 질환의 예방 또는 치료용 약제학적 복합제제
CN112274490B (zh) * 2020-11-19 2022-11-22 四川尚锐生物医药有限公司 一种氨氯地平氯沙坦钾复方组合物的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
EP0736021A4 (en) 1993-12-23 1997-04-02 Merck & Co Inc LOSARTANE POLYMORPHS AND PROCESS FOR THE PREPARATION OF FORM II OF LOSARTANE
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
US6677356B1 (en) * 1999-08-24 2004-01-13 Medicure International Inc. Treatment of cardiovascular and related pathologies
EP1106210A3 (en) * 1999-12-07 2003-12-03 Pfizer Products Inc. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications
WO2002002081A1 (en) * 2000-07-05 2002-01-10 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and methods of using same
EP1314425A4 (en) 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
EP1448190A2 (en) 2001-10-18 2004-08-25 Novartis AG Salts formed of an at1-receptor antagonist and a cardiovascular agent
HUP0501067A2 (en) 2001-11-14 2006-02-28 Teva Pharma Amorphous and crystalline forms of losartan potassium and process for their preparation
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US7157100B2 (en) 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
WO2004067512A1 (en) 2003-01-27 2004-08-12 Hanmi Pharm. Co., Ltd. Stable amorphous amlodipine camsylate, process for preparing same and composition for oral administration thereof
EP1648357A2 (en) * 2003-07-18 2006-04-26 Pneu Medex Inc. Fluid operated actuators and pneumatic unloading orthoses
WO2005011646A2 (en) 2003-07-31 2005-02-10 Nicox S.A. Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases
WO2005070463A2 (en) * 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
CN103083318A (zh) * 2004-11-05 2013-05-08 贝林格尔.英格海姆国际有限公司 包含替米沙坦和氨氯地平的双层片剂
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
TWI388345B (zh) 2005-06-27 2013-03-11 Sankyo Co 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型
JP5063370B2 (ja) 2005-06-27 2012-10-31 第一三共株式会社 湿式造粒製薬の調製方法
US20090304755A1 (en) * 2005-10-27 2009-12-10 Raghu Rami Reddy Kasu Pharmaceutical formulation of losartan
JP2009514961A (ja) 2005-11-08 2009-04-09 ノバルティス アクチエンゲゼルシャフト アンギオテンシンｉｉ受容体ブロッカー、カルシウムチャネルブロッカーおよび他の活性剤の組合せ
EP1962811B1 (en) * 2005-12-22 2016-04-27 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
KR100742432B1 (ko) * 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
KR100913791B1 (ko) 2006-07-21 2009-08-26 한미약품 주식회사 (ｓ)-(-)-암로디핀 캠실레이트 또는 이의 수화물 및 이를함유하는 약학적 조성물
US20080051438A1 (en) 2006-08-11 2008-02-28 Shinobu Nagahama Preventive/Therapeutic Compositions Useful for Treating Cardiovascular Diseases
WO2008023869A1 (en) 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023958A1 (en) 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
US20080241240A1 (en) 2006-08-24 2008-10-02 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR101247583B1 (ko) 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
EP2413931B1 (en) 2009-01-23 2016-06-01 Hanmi Science Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same

Also Published As

Publication number Publication date
UA102721C2 (uk) 2013-08-12
ES2505116T3 (es) 2014-10-09
CR20110449A (es) 2011-11-10
TW201031404A (en) 2010-09-01
AR075027A1 (es) 2011-03-02
KR20100086913A (ko) 2010-08-02
EP2413931B1 (en) 2016-06-01
AU2009338280A1 (en) 2011-09-15
CA2749957C (en) 2016-07-26
CN102292084B (zh) 2014-01-29
MA33057B1 (fr) 2012-02-01
NI201100145A (es) 2012-08-17
ES2580777T8 (es) 2016-09-22
MX2011006008A (es) 2011-06-28
JP5466716B2 (ja) 2014-04-09
AU2009338267A1 (en) 2011-09-15
MX2011006009A (es) 2011-06-28
SG173046A1 (en) 2011-08-29
NZ594738A (en) 2013-11-29
AU2009338251B2 (en) 2014-03-13
AU2009338267A2 (en) 2011-09-29
EA020103B1 (ru) 2014-08-29
CL2011001781A1 (es) 2012-03-23
MX345868B (es) 2017-02-21
BRPI0924136B8 (pt) 2021-05-25
IL214147A (en) 2016-08-31
HK1163539A1 (en) 2012-09-14
SA110310070B1 (ar) 2014-09-02
CR20110448A (es) 2011-11-10
ZA201106161B (en) 2012-10-31
PE20120428A1 (es) 2012-05-17
BRPI0924136B1 (pt) 2019-10-15
SG173044A1 (en) 2011-08-29
CO6361915A2 (es) 2012-01-20
AU2009338280B2 (en) 2014-05-01
CA2749957A1 (en) 2010-07-29
CO6361905A2 (es) 2012-01-20
SG173045A1 (en) 2011-08-29
HN2011002022A (es) 2014-02-03
EA201170958A1 (ru) 2012-01-30
EP2391365B1 (en) 2014-11-26
ZA201106160B (en) 2012-10-31
BRPI0924137A2 (pt) 2019-09-24
JP2012515767A (ja) 2012-07-12
IL214145A0 (en) 2011-08-31
JO3328B1 (ar) 2019-03-13
JP5658172B2 (ja) 2015-01-21
JP2012515768A (ja) 2012-07-12
EP2391365A2 (en) 2011-12-07
KR20100086921A (ko) 2010-08-02
UY32388A (es) 2010-02-26
MA33058B1 (fr) 2012-02-01
CN105998017A (zh) 2016-10-12
ZA201106162B (en) 2012-10-31
MX2011006061A (es) 2011-06-24
EP2391348A1 (en) 2011-12-07
UA105203C2 (ru) 2014-04-25
NZ594739A (en) 2013-11-29
CN102292070A (zh) 2011-12-21
CA2749955C (en) 2016-07-26
US20110245301A1 (en) 2011-10-06
EA021763B1 (ru) 2015-08-31
AU2009338251A1 (en) 2011-09-15
CA2749903C (en) 2016-09-06
MX349221B (es) 2017-07-19
EA019471B1 (ru) 2014-03-31
US8673945B2 (en) 2014-03-18
NI201100144A (es) 2012-11-06
JP5660544B2 (ja) 2015-01-28
US9161933B2 (en) 2015-10-20
PE20100559A1 (es) 2010-09-12
ECSP11011253A (es) 2011-09-30
TW201028151A (en) 2010-08-01
TWI404534B (zh) 2013-08-11
CN102292084A (zh) 2011-12-21
BRPI0924136A2 (pt) 2017-06-13
US8673944B2 (en) 2014-03-18
HN2011002020A (es) 2014-02-03
US20110251245A1 (en) 2011-10-13
MY151550A (en) 2014-06-13
UY32389A (es) 2010-02-26
KR101232296B1 (ko) 2013-02-13
CA2749955A1 (en) 2010-07-29
WO2010085014A1 (en) 2010-07-29
MY150974A (en) 2014-03-31
MA33056B1 (fr) 2012-02-01
PE20100739A1 (es) 2010-11-19
WO2010085047A2 (en) 2010-07-29
MX345956B (es) 2017-02-28
CR20110450A (es) 2011-11-10
AR075028A1 (es) 2011-03-02
AU2009338267B2 (en) 2014-09-18
NZ594740A (en) 2013-11-29
TWI395583B (zh) 2013-05-11
CN102292085B (zh) 2017-01-18
IL214147A0 (en) 2011-08-31
AR070897A1 (es) 2010-05-12
WO2010085027A1 (en) 2010-07-29
PE20140978A1 (es) 2014-08-16
IL214146A0 (en) 2011-08-31
DOP2011000231A (es) 2011-10-15
CN102292085A (zh) 2011-12-21
ES2580777T3 (es) 2016-08-26
JO2981B1 (ar) 2016-09-05
US20110245302A1 (en) 2011-10-06
JP2012515770A (ja) 2012-07-12
EP2391348B1 (en) 2014-08-27
EP2391365A4 (en) 2012-07-25
CO6361914A2 (es) 2012-01-20
WO2010085047A3 (en) 2010-11-04
BRPI0924135A2 (pt) 2016-02-10
EA201170959A1 (ru) 2011-12-30
NI201100143A (es) 2012-08-17
KR101160151B1 (ko) 2012-06-27
CA2749903A1 (en) 2010-07-29
MY173823A (en) 2020-02-24
DOP2011000230A (es) 2011-10-15
BRPI0924136A8 (pt) 2017-10-03
EP2413931A4 (en) 2012-08-08
ES2526606T3 (es) 2015-01-13
EP2413931A1 (en) 2012-02-08
EA201170960A1 (ru) 2012-01-30
EP2391348A4 (en) 2012-07-25
UA102720C2 (ru) 2013-08-12

Similar Documents

Publication Publication Date Title
DOP2011000229A (es) Composicion farmaceutica solida que comprende amlodipina y losartan
ECSP22034515A (es) FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
CL2014000759A1 (es) Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición.
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
CL2007003713A1 (es) Compuestos derivados de 2-amino-4-oxo-3,5-dihidroimidazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir una patologia relacionada con abeta, tales como alzheimer, parkinson, sindrome de down, entre otras
ECSP088980A (es) Composicion farmacéutica que comprende amlodipina y losartán
ECSP12011585A (es) Compuestos y composiciones para eltratamiento de enfermedades parasitarias
DOP2016000253A (es) Nuevos compuestos
UY30365A1 (es) Comprimido bicapa para la prevención de los accidentes cardiovasculares
CR20120623A (es) Composiciones Farmacéuticas que comprenden Monohidrato de Lactato de 4-amino-5-Fluoro-3-[6-(4-Metil-Piperazin-1-Il)-1H- Bencimidazol-2-Il]-1H-Quinolin-2-Ona
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
PE20142043A1 (es) Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos
CL2012000316A1 (es) Compuestos fungicidas derivados de n1-acil-5-fluoro-pirimidinona; composiciones que los comprenden y metodo que los emplea para combatir hongos fitopatogenos.
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
ECSP11011251A (es) Composición farmacéutica sólida que comprende amlodipina y losartan con estabilidad mejorada.
UY33789A (es) Combinación que comprende un derivado de la familia de las combretastatinas y cetuximab